Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary of the Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals. Its pharmaceutical division provides active pharmaceutical ingredients and intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose. In Asia, Kolon TissueGene has licensed intellectual property rights to Kolon Life Science (KLS) for commercialization of TG-C. Through Kolon Life Science, we have been able to expedite commercialization of our products by conducting clinical trials in both the U.S. and Korea. In July 2017, Kolon Life Science received marketing approval in Korea from the Korea Ministry of Food and Drug Safety (MFDS).
Learn More About Kolon Life Science
Kolon TissueGene, Inc., is an advanced cell therapies company targeting musculoskeletal and degenerative disorders. Our focus is on using cell and gene therapies to provide game-changing medicines that transform the paradigm in patient treatment. We seek partners who share our vision in the exciting promise of advanced therapies to truly provide a shift in patient care.
Tell us more about yourself and your company's initiatives.
